Caribou Biosciences Announces the FDA has Granted Fast Track ...
WEBSep 3, 2024 — CB-010, an allogeneic anti-CD19 CAR-T cell therapy, will be evaluated in the GALLOP Phase 1 clinical trial in patients with lupus nephritis (LN) and extrarenal lupus (ERL), subcategories of SLE. The GALLOP clinical trial …
Caribou Biosciences (CRBU): CB-010, chRDNA Technology …
WEB2 days ago — CRBU's flagship candidate, CB-010, shows promising results in Phase 1 trials for large B cell lymphoma, with long-term complete response rates. The FDA's Fast Track Designation for CB-010 and...
Caribou Biosciences Expands Clinical Development of CB-010 with …
WEBApr 4, 2024 — CB-010 is the lead clinical-stage product candidate from Caribou’s allogeneic CAR-T cell therapy platform. As previously reported, CB-010 has demonstrated encouraging initial safety and...
Caribou Biosciences Expands Clinical Development of CB-010 with …
WEBApr 4, 2024 — CB-010 targets CD19, a protein on the surface of B cells, and has a PD-1 knockout (KO) that reduces CAR-T cell exhaustion. CB-010 holds the potential for deep depletion of disease-causing B cells which could reset the immune system, leading to sustained drug-free remission.
Caribou Biosciences Announces Positive Initial Data for CB-010 …
WEBMay 12, 2022 — CB-010 is the lead product candidate from Caribou’s allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) in the ongoing ANTLER Phase 1 trial.
Caribou Biosciences Announces the FDA Granted Regenerative …
WEBNov 29, 2022 — CB-010 is the first allogeneic anti-CD19 CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to improve the persistence of antitumor activity by limiting...
Caribou Biosciences Announces Positive Initial Data for CB-010 …
WEBMay 12, 2022 — CB-010 is an allogeneic anti-CD19 CAR-T cell therapy engineered using Cas9 CRISPR hybrid RNA-DNA (chRDNA) technology to insert a CD19-specific CAR into the TRAC gene and knock out PD-1 to boost...
Pipeline | CB-010 | CB-011 | CB-012 | CB-020 | Caribou Biosciences
WEBCB-010 is the first allogeneic CAR-T cell therapy, to our knowledge, in a clinical trial with a PD-1 knockout, a genome-editing strategy designed to improve antitumor activity by limiting premature CAR-T cell exhaustion.
Caribou Biosciences Announces the FDA has Granted Fast Track ...
WEBSep 3, 2024 — CB-010, an allogeneic anti-CD19 CAR-T cell therapy, will be evaluated in the GALLOP Phase 1 clinical trial in patients with lupus nephritis (LN) and extrarenal lupus (ERL),...
Caribou Biosciences Reports Positive Clinical Data from
WEBJul 13, 2023 — “CB-010 dose escalation data rival the responses from autologous cell therapies and demonstrate the potential utility of an off-the-shelf CAR-T cell therapy that could, if approved, provide...